SCM
OBIO icon

Sterling Capital Management’s Orchestra BioMed OBIO Stock Holding History

Sterling Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$604 Buy
+140
New +$573 ﹤0.01% 3207
2025
Q2 		– Sell
-247
Closed -$1.06K – 3352
2025
Q1 		$1.06K Sell
247
-215
-47% -$1.07K ﹤0.01% 2793
2024
Q4 		$1.85K Buy
462
+409
+772% +$2.2K ﹤0.01% 2803
2024
Q3 		$272 Buy
+53
New +$346 ﹤0.01% 3055

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Sterling Capital Management's OBIO Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Orchestra BioMed (OBIO) in Q2 2026: 140 shares worth $604. The stake represents ﹤0.01% of the portfolio and ranks #3207 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in OBIO as recently as Q1 2025.

Sterling Capital Management first reported a position in OBIO in Q3 2024 and has held it in 4 quarters since. The position peaked at $1.85K in Q4 2024. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Sterling Capital Management held 140 shares of Orchestra BioMed worth $604 as of Q2 2026.
  • Orchestra BioMed was a new Sterling Capital Management position in Q2 2026.
  • Orchestra BioMed made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3207 holding.
  • Sterling Capital Management first reported a position in Orchestra BioMed in Q3 2024 and has held it in 4 quarters since.
  • Sterling Capital Management's Orchestra BioMed position peaked at $1.85K in Q4 2024.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.